首页|我国鼓励创新药出海政策的相关考量

我国鼓励创新药出海政策的相关考量

扫码查看
近年来我国鼓励创新政策在药品研发创新和出海等方面已经初见成效,在当前经济增速放缓的内外部多重压力下,我国创新药出海有助于打开市场空间,实现国内国外双循环,反哺国内研发,值得在政策方面持续助力和加码.日本医药行业在20世纪也遇到了人口老龄化和经济增长放缓的问题,一系列鼓励创新和出海政策的出台助力部分药企成功走向了全球市场,相关经验值得我国借鉴.本文概述了目前我国创新药出海的现状,分析总结了日本的成功经验,并从总体产业政策角度建议医药政策继续坚定不移地鼓励创新,从源头上引导药企进行以临床价值为导向的创新,支持有能力的药企出海布局,在政策、资金等方面对具有全球创新能力的药企给予支持.
China's Policy Considerations for Encouraging the Internationalization of Innovative Drugs
In recent years,China's policy of encouraging innovation has begun to yield significant results in promoting drug research,development,and international expansion.Amid the current economic slowdown and various internal and external pressures,the internationalization of China's innovative drugs helps to expand market reach and facilitate the"dual circulation"strategy,thereby benefiting domestic research and development.Continued policy support and enhancement in this area are crucial.Japan's pharmaceutical industry faced similar challenges in the 20th century,including population aging and economic stagnation.The implementation of policies encouraging innovation and internationalization enabled some companies to successfully enter global markets.China can draw valuable lessons from these successes.This paper provides an overview of the current status of China's innovative drugs going global,analyzes Japan's successful experience,and offers policy recommendations.It is recommended that pharmaceutical policies continue to firmly promote innovation,encourage drug companies to focus on clinical value-driven research from the outset,support capable companies in expanding internationally,and provide assistance in terms of policies and funding to globally competitive enterprises.

population aginginnovative drugs internationalizationencouraging innovationglobalizationindustrial policy

胡骏

展开 >

上海市药品和医疗器械不良反应监测中心

人口老龄化 创新药出海 鼓励创新 全球化 产业政策

2024

中国食品药品监管
中国医药报社

中国食品药品监管

影响因子:0.099
ISSN:1673-5390
年,卷(期):2024.(11)